{
  "docId": "019de075-60f4-719a-882e-3143e28b60e4",
  "docSlug": "fdbc224a3aaf8eece0f490c97a32599d",
  "documentTitle": "MAIA Biotechnology | Investor Presentation Deck | 35 slides",
  "authorId": "maia-biotechnology",
  "authorName": "MAIA Biotechnology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 35,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": "The slide highlights exceptional progression-free survival in a high-need patient population.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-60f4-719a-882e-3143e28b60e4/15",
  "deckHref": "/decks/019de075-60f4-719a-882e-3143e28b60e4",
  "deckJsonHref": "/decks/019de075-60f4-719a-882e-3143e28b60e4.json",
  "deckAnchorHref": "/decks/019de075-60f4-719a-882e-3143e28b60e4#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "The first 2 patients enrolled in Part A of the study continue to be alive, approximately 12.2 and 11.5 months respectively, from treatment initiation. Both patients have advanced Stage IV metastatic disease and are heavily pretreated, receiving third line of therapy after previously failing treatment with an immune checkpoint inhibitor. They continue to be progression free following their last dose, 10.2 and 8.5 months respectively, with no new treatment. In real-world clinical practice, observed survival in such heavily pretreated patients is 3-4 months with treatment; weeks without new treatment",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cbca4f7d-d2c0-44e7-99ef-79408fd107ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "PRELIMINARY SURVIVAL DATA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8223ebb3-e094-4fef-8f4e-ce122eaeb893",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Storytelling: audience calibration",
      "slug": "audience",
      "agent": "storyteller",
      "layer": "slide",
      "matchId": "d9925e03-37bb-4635-a7ed-a2890ddf038a",
      "evidence": "The first 2 patients enrolled in Part A of the study continue to be alive, approximately 12.2 and 11.5 months respectively, from treatment initiation.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}